Immunome shares are trading higher after the company announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals to acquire AL102 and AL101 drug candidates.
Portfolio Pulse from Benzinga Newsdesk
Immunome's stock price increased following the announcement of a definitive asset purchase agreement with Ayala Pharmaceuticals for the acquisition of AL102 and AL101 drug candidates.
February 06, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunome's shares are trading higher after announcing the acquisition of AL102 and AL101 from Ayala Pharmaceuticals.
The acquisition of AL102 and AL101 drug candidates by Immunome is seen as a positive development, indicating potential growth and expansion in its product pipeline. This strategic move is likely to boost investor confidence in Immunome's future prospects, leading to a short-term increase in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90